Skip to main content
Journal cover image

Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin.

Publication ,  Journal Article
Ansell, JE; Laulicht, BE; Bakhru, SH; Hoffman, M; Steiner, SS; Costin, JC
Published in: Thromb Res
October 2016

UNLABELLED: Major bleeding with low molecular weight heparin (LMWH) therapy occurs in up to 5% of patients and its anticoagulation is only partially reversed by protamine sulfate. We studied the ability of ciraparantag (PER977), a novel agent that reverses LMWH in preclinical studies, to reverse LMWH in healthy volunteers. METHODS: In this phase 1/2 trial, 4 cohorts of 10 healthy volunteers received escalating doses of ciraparantag (100 to 300mg) or placebo (8:2 ratio) approximately 4h after a single subcutaneous dose of enoxaparin, 1.5mg/kg. Safety, pharmacokinetic and pharmacodynamic effects were assessed. RESULTS: Complete reversal of enoxaparin anticoagulation, measured by a reduction of whole blood clotting time, was observed in all subjects who received a single ciraparantag dose ranging from 100mg to 300mg. The anticoagulation reversal occurred rapidly after bolus injection and persisted for the duration of the study. At 12h and 24h, the differences in whole blood clotting time in the treated group compared to placebo were no longer significant, consistent with the decline in enoxaparin concentrations and anticoagulation effects. No procoagulant signals were detected as measured by D-dimer, F1.2, and tissue factor pathway inhibitor levels. Ciraparantag was well tolerated with only transient, minor side effects. CONCLUSION: Ciraparantag reverses the whole blood clotting time induced by enoxaparin in a dose related manner and produces no procoagulant signal or deleterious adverse events in doses up to 300mg.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Thromb Res

DOI

EISSN

1879-2472

Publication Date

October 2016

Volume

146

Start / End Page

113 / 118

Location

United States

Related Subject Headings

  • Young Adult
  • Piperazines
  • Middle Aged
  • Male
  • Humans
  • Heparin, Low-Molecular-Weight
  • Healthy Volunteers
  • Female
  • Cardiovascular System & Hematology
  • Arginine
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ansell, J. E., Laulicht, B. E., Bakhru, S. H., Hoffman, M., Steiner, S. S., & Costin, J. C. (2016). Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin. Thromb Res, 146, 113–118. https://doi.org/10.1016/j.thromres.2016.07.008
Ansell, Jack E., Bryan E. Laulicht, Sasha H. Bakhru, Maureane Hoffman, Solomon S. Steiner, and James C. Costin. “Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin.Thromb Res 146 (October 2016): 113–18. https://doi.org/10.1016/j.thromres.2016.07.008.
Ansell JE, Laulicht BE, Bakhru SH, Hoffman M, Steiner SS, Costin JC. Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin. Thromb Res. 2016 Oct;146:113–8.
Ansell, Jack E., et al. “Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin.Thromb Res, vol. 146, Oct. 2016, pp. 113–18. Pubmed, doi:10.1016/j.thromres.2016.07.008.
Ansell JE, Laulicht BE, Bakhru SH, Hoffman M, Steiner SS, Costin JC. Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin. Thromb Res. 2016 Oct;146:113–118.
Journal cover image

Published In

Thromb Res

DOI

EISSN

1879-2472

Publication Date

October 2016

Volume

146

Start / End Page

113 / 118

Location

United States

Related Subject Headings

  • Young Adult
  • Piperazines
  • Middle Aged
  • Male
  • Humans
  • Heparin, Low-Molecular-Weight
  • Healthy Volunteers
  • Female
  • Cardiovascular System & Hematology
  • Arginine